文献速递外周动脉疾病

紫杉醇涂层外周动脉器械与死亡率增加无关

Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
PubMed 文献 · J Vasc Surg · 2020-01-06

单中心回顾性研究纳入2011-2018年1170例股腘动脉经皮血运重建患者,比较紫杉醇涂层器械(652例)与无涂层器械(518例)的长期死亡率。结论认为紫杉醇涂层器械不增加3.5年内死亡率。

要点

  • 紫杉醇涂层器械在3.5年随访内未增加全因死亡率。
  • 3年和3.5年时紫杉醇组死亡率反而显著低于无涂层组。
  • 年龄、透析、慢性肢体威胁性缺血、慢性肾病和充血性心衰是独立死亡危险因素。

核心结论

  • 与无涂层器械相比,紫杉醇涂层球囊和支架在3.5年内不增加死亡率。
  • 紫杉醇涂层器械可继续谨慎使用,尤其对于再狭窄风险增高的患者。
  • 需要进一步长期研究来确定晚期死亡风险。

研究设计与样本

  • 回顾性单中心研究,纳入2011-2018年连续1170例接受股腘动脉经皮血运重建的患者。
  • 紫杉醇组652例,无涂层组518例;主要结局为全因死亡率。
  • 采用卡方检验、Wilcoxon符号秩检验、多因素logistic回归和Kaplan-Meier生存分析。

主要发现

  • 按糖尿病、慢性肾病、慢性肢体威胁性缺血或紫杉醇涂层球囊制造商分亚组,生存率无显著差异。
  • 多因素分析显示年龄、透析、慢性肢体威胁性缺血、慢性肾病和充血性心衰是死亡的独立危险因素,而紫杉醇使用与较低死亡率相关。

临床怎么用

  • 对于股腘动脉病变需血运重建的患者,紫杉醇涂层器械不增加3.5年内死亡风险,可谨慎选用。
  • 对再狭窄风险增高的患者,紫杉醇涂层器械仍可考虑使用,但需持续关注长期安全性。

局限性

  • 回顾性单中心研究设计。
  • 紫杉醇组与无涂层组在糖尿病、透析和肌酐水平上存在基线差异。
  • 随访时间限于3.5年,晚期死亡风险仍需进一步长期研究确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term safety concerns have been raised that the use of paclitaxel-coated balloons and stents is linked to excess mortality. Our objective was to compare outcomes in patients treated with paclitaxel vs uncoated devices and to analyze long-term mortality. METHODS: We conducted a retrospective single-institution review of 1170 consecutive patients who underwent femoropopliteal percutaneous revascularization by angioplasty, atherectomy, stent placement, or combination between 2011 and 2018. The primary outcome measure was all-cause mortality. Groups were divided into patients who received paclitaxel (n = 652) and those who did not (n = 518). Categorical variables were assessed using χ2 analysis and continuous variables with the Wilcoxon signed rank test. A multivariable analysis was performed using multivariable logistic regression models. Mortality was compared using Kaplan-Meier survival analysis. RESULTS: Demographics, risk factors, and Rutherford class were similar between the groups, except that the paclitaxel group was more likely to have diabetes (60.9% vs 55.0%; P = .04), was less likely to be on dialysis (10.7% vs 14.9%; P = .04), and had lower average creatinine concentration (1.6 ± 1.8 mg/dL vs 2.0 ± 2.3 mg/dL; P = .003). There were no differences in all-cause mortality through 2 years between paclitaxel and no-paclitaxel cohorts (25.5% vs 30.3%; log-rank, P = .098). At 3 years and 3.5 years, mortality was significantly lower in the paclitaxel group: year 3, 32.1% vs 39.4% (log-rank, P = .041); year 3.5, 35.2% vs 43.9% (log-rank, P = .027). Survival rates were not significantly different in examining subgroups by diabetes, chronic kidney disease, presence of chronic limb-threatening ischemia, or paclitaxel-coated balloon manufacturer. Multivariable analysis demonstrated that age, dialysis, chronic limb-threatening ischemia, chronic kidney disease, and congestive heart failure were independent risk factors for mortality, whereas paclitaxel use was associated with lower mortality. CONCLUSIONS: The use of paclitaxel-coated balloons and stents does not increase mortality compared with uncoated devices out to 3.5 years. Paclitaxel-coated devices can be used with continued caution, especially in patients at increased risk of restenosis. Further long-term studies are needed to determine the risk of late mortality.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kumins NH, King AH, Ambani RN, et al. Paclitaxel-coated peripheral artery devices are not associated with increased mortality. J Vasc Surg. 2020. PMID: 31917036. doi:10.1016/j.jvs.2019.10.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。